Your browser is no longer supported. Please, upgrade your browser.
Cardiovascular Systems, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own1.10% Shs Outstand38.91M Perf Week-12.04%
Market Cap1.56B Forward P/E- EPS next Y-0.11 Insider Trans0.00% Shs Float38.80M Perf Month-2.60%
Income-20.20M PEG- EPS next Q-0.12 Inst Own94.60% Short Float2.93% Perf Quarter-14.54%
Sales228.40M P/S6.84 EPS this Y75.90% Inst Trans0.19% Short Ratio6.13 Perf Half Y-2.17%
Book/sh6.95 P/B5.10 EPS next Y63.20% ROA-6.80% Target Price47.00 Perf Year-7.52%
Cash/sh4.79 P/C7.40 EPS next 5Y33.70% ROE-8.60% 52W Range27.70 - 48.28 Perf YTD-18.96%
Dividend- P/FCF- EPS past 5Y5.20% ROI-9.30% 52W High-28.50% Beta0.84
Dividend %- Quick Ratio5.00 Sales past 5Y5.40% Gross Margin78.60% 52W Low24.62% ATR1.59
Employees779 Current Ratio5.70 Sales Q/Q3.40% Oper. Margin-9.50% RSI (14)25.80 Volatility5.61% 3.62%
OptionableYes Debt/Eq0.08 EPS Q/Q-82.40% Profit Margin-10.20% Rel Volume0.98 Prev Close35.47
ShortableYes LT Debt/Eq0.08 EarningsMay 06 AMC Payout- Avg Volume185.62K Price34.52
Recom2.20 SMA20-11.97% SMA50-12.49% SMA200-9.48% Volume158,532 Change-2.66%
Nov-05-20Reiterated Needham Buy $44 → $47
Jul-22-20Initiated Northland Capital Outperform $40
Jul-17-20Initiated Barclays Overweight
Jun-11-20Upgrade Needham Hold → Buy
Apr-07-20Initiated Oppenheimer Outperform $47
Oct-18-19Initiated Guggenheim Buy
Apr-11-19Downgrade BofA/Merrill Buy → Underperform $51 → $42
Aug-22-18Initiated Stifel Buy $45
Jun-27-18Upgrade BofA/Merrill Underperform → Buy
Dec-15-17Downgrade Needham Buy → Hold
Oct-26-17Reiterated Needham Buy $37 → $36
Sep-22-17Initiated Raymond James Mkt Perform
Jun-21-17Downgrade BofA/Merrill Neutral → Underperform
Jan-30-17Initiated Lake Street Buy $40
Jan-26-17Reiterated Needham Buy $27 → $32
Oct-07-16Resumed JMP Securities Mkt Outperform
Aug-22-16Upgrade Leerink Partners Mkt Perform → Outperform
Aug-04-16Upgrade BofA/Merrill Underperform → Neutral
Aug-04-16Reiterated Needham Buy $23 → $27
Jun-29-16Reiterated Needham Buy $20 → $23
May-06-21 07:31PM  
May-03-21 04:05PM  
Apr-27-21 07:00AM  
Apr-15-21 07:00PM  
Apr-09-21 08:25AM  
Apr-08-21 07:00AM  
Apr-05-21 03:10AM  
Mar-24-21 07:00AM  
Mar-23-21 07:56AM  
Mar-22-21 09:00AM  
Mar-18-21 07:27AM  
Mar-17-21 07:00AM  
Mar-05-21 11:30AM  
Feb-14-21 01:32PM  
Feb-11-21 07:00AM  
Feb-09-21 09:56AM  
Feb-08-21 04:05PM  
Feb-04-21 01:34PM  
Feb-03-21 10:30PM  
Feb-02-21 10:22AM  
Feb-01-21 07:00AM  
Jan-27-21 05:00PM  
Jan-19-21 09:00AM  
Jan-18-21 04:05PM  
Jan-13-21 07:00AM  
Jan-04-21 04:05PM  
Dec-18-20 08:28PM  
Dec-04-20 11:31AM  
Nov-11-20 07:00AM  
Nov-06-20 08:46AM  
Nov-04-20 08:31PM  
Nov-03-20 10:08AM  
Oct-28-20 12:32PM  
Oct-21-20 07:00AM  
Oct-14-20 08:00AM  
Oct-12-20 01:00PM  
Oct-07-20 07:00AM  
Sep-15-20 10:01AM  
Sep-03-20 11:31AM  
Aug-20-20 04:05PM  
Aug-19-20 11:38AM  
Aug-17-20 02:55AM  
Aug-06-20 10:43AM  
Aug-05-20 01:31AM  
Aug-04-20 06:45PM  
Aug-03-20 12:48PM  
Jul-28-20 12:33PM  
Jul-27-20 04:05PM  
Jul-22-20 09:35AM  
Jul-14-20 07:00AM  
Jul-09-20 05:23PM  
Jul-05-20 05:05PM  
Jun-18-20 08:40AM  
Jun-11-20 04:05PM  
Jun-10-20 01:25PM  
Jun-09-20 10:32PM  
May-28-20 05:06AM  
May-06-20 10:44AM  
May-05-20 06:45PM  
Apr-28-20 12:33PM  
Apr-21-20 07:00AM  
Apr-14-20 01:34PM  
Mar-06-20 11:30AM  
Feb-20-20 08:00AM  
Feb-18-20 05:00PM  
Feb-17-20 09:31AM  
Feb-11-20 05:24PM  
Feb-06-20 08:14AM  
Feb-05-20 05:55PM  
Jan-29-20 12:31PM  
Jan-20-20 09:49AM  
Jan-18-20 12:41PM  
Jan-15-20 07:00AM  
Dec-20-19 06:01AM  
Dec-17-19 08:22AM  
Dec-16-19 07:00AM  
Dec-11-19 11:02PM  
Dec-02-19 08:40PM  
Nov-28-19 09:31AM  
Nov-12-19 05:00PM  
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sedo SandraChief Compliance OfficerAug 24Sale31.942,91493,06767,467Aug 26 04:34 PM
Rosenstein AlexanderGeneral Counsel & Corp. Sec.Aug 24Sale31.944,692149,85384,145Aug 26 04:34 PM
Sedo SandraChief Compliance OfficerAug 18Sale32.8944014,47174,280Aug 20 04:48 PM
Paulsen ErikDirectorAug 17Buy32.852006,570200Aug 19 08:46 AM
Robb Rhonda J.Chief Operating OfficerAug 14Buy31.971,00031,969167,106Aug 17 11:31 AM
Aronson Martha GoldbergDirectorAug 13Buy32.223,00096,6556,000Aug 17 11:31 AM
Ward Scott R.Chairman and CEOAug 13Buy32.191,00032,187581,332Aug 17 11:30 AM
Points Jeffrey S.Chief Financial OfficerAug 13Buy32.011,00032,01085,841Aug 17 11:30 AM
Rosenstein AlexanderGeneral Counsel & Corp. Sec.Aug 13Sale31.9668521,89393,491Aug 17 04:57 PM